After an initial decrease, platelet and neutrophil counts stabilized with Jakafi® (ruxolitinib)1
In REACH2, no clinically meaningful differences in platelet and neutrophil counts were observed over time in patients receiving Jakafi vs those in the control group1
Platelet Counts (109/L) Over Time1,a,b
![Platelet counts over time chart](/acute-graft-versus-host-disease/sites/g/files/hssmmz3786/files/2024-03/chart-agvhd-platelet-counts-ot.webp)
![](/acute-graft-versus-host-disease/sites/g/files/hssmmz3786/files/2024-03/quote-start.webp)
![Dr Pashna Munshi](/acute-graft-versus-host-disease/sites/g/files/hssmmz3786/files/2024-03/md-munshi-profile.webp)
In my practice, I’m comfortable initiating Jakafi in appropriate steroid-refractory acute GVHD patients when platelet counts are at or above 20,000, and as long as patients are not transfusion dependent.
Pashna Munshi, MD
GVHD Expert
![](/acute-graft-versus-host-disease/sites/g/files/hssmmz3786/files/2024-03/quote-end.webp)
- aPlot shows boxes (25th-75th percentiles) with median as horizontal line. The dots in the boxes and joint lines represent the mean values. Whiskers (vertical lines) extend to the 10th-90th percentiles.1
- bValues outside this range are not displayed.1
![Neutrophil counts over time chart](/acute-graft-versus-host-disease/sites/g/files/hssmmz3786/files/2024-03/chart-agvhd-neutrophil-counts-ot.webp)
- aPlot shows boxes (25th-75th percentiles) with median as horizontal line. The dots in the boxes and joint lines represent the mean values. Whiskers (vertical lines) extend to the 10th-90th percentiles.1
- bValues outside this range are not displayed.1
GVHD=graft-versus-host disease; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
Reference: 1. Data on file. Incyte Corporation. Wilmington, DE.